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This prospective trial assessed the safety and efficacy of allogeneic hematopoietic stem cell transplantation
from a HLA-matched donor with a reduced-intensity regimen (RIST) consisting of iv fludarabine 30 mg/m2
for 6 days and oral busulfan 4 mg/kg/day for 2 days in patients older than 50 years with hematological
malignancies. Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-
versus-host disease prophylaxis. After 30 patients had been enrolled, an interim analysis was performed,
and this report focuses on a precise evaluation of the toxicity profile and chimerism kinetics. Sustained
engraftment in all patients, no severe regimen-related toxicity (RRT) within 20 days, and no transplant-
related mortality through Day 100 were observed. T-cell (CD3+) full-donor (over 90%) chimerism was
observed in 22 of the 30 patients, while the remaining eight had mixed-donor chimerism over 77% on Day
90. Thereafter, five subsequently converted to full-donor chimerism without donor lymphocyte infusion by
day 120 (n = 4) or Day 180 (n = 1). Two showed persistent mixed chimerism without relapse through Day
180. Grade III–IV acute graft-versus-host disease and extensive chronic graft-versus-host disease occurred
in 10% and 73%, respectively. With a median follow-up of 1.5 years, overall survival and disease-free sur-
vival at 1 year was 83% and 62%, respectively. Seven patients hematologically relapsed overall, and five of
them had myelodysplastic syndrome with poor prognostic factors. In older patients, RIST with fludarabine
and busulfan was associated with acceptable toxicities and a satisfactory antileukemia effect, regardless of
the early chimerism status. Am. J. Hematol. 82:873–880, 2007. VC 2007 Wiley-Liss, Inc.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT)
is a potentially curative treatment of choice for hematological
malignancies. However, many centers limit HSCT to younger
patients because of the threat of a higher risk of treatment-
related toxicities including graft-versus-host disease (GvHD),
nonrelapse mortality, and lower disease-free survival (DFS)
in the older population, although the median age of onset of
chronic myeloid leukemia (CML) is in the sixth decade of life,
and the peak incidence of acute myeloid leukemia (AML)
and myelodysplastic syndrome (MDS) is in the seventh
decade. To overcome this obstacle, allogeneic HSCT with a
reduced-intensity (RIST) or nonmyeloablative conditioning
regimen has recently been explored for patients who are
ineligible to receive conventional myeloablative HSCT
(CIST) due to age limits or comorbidities. Many studies sug-
gested that RIST is a reasonable option for older patients or
patients with comobidities with acceptable treatment-related
complications or morbidity, while preserving adequate anti-
tumor effects [1–12]. However, these studies mostly pursued
different variables including disease types, stages [1,4–6,
8,12], donor type [1,2,5,10], graft source [1,2], conditioning
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regimens [4,5,7,9], and/or GvHD prophylaxis [1,4,9]. This
makes overall interpretation of studies difficult. Additionally,
there has been no study to prospectively assess whether
RIST consisting of 180 mg fludarabine plus 8 mg/kg busulfan
without antithymocyte globulin actually produces less signifi-
cant organ toxicities and treatment-related toxicities in an
older patient population. Information regarding the impact of
the speed and degree of lineage-specific donor chimerism on
clinical outcomes after RIST in older patients has been limited
[3,8,13–17]. Moreover, even studies evaluated with more ho-
mogeneous patient population, type of GvHD prophylaxis
and/or tempo of withdrawal of immunosuppressive agents
varied depending on transplant centers and a feasible prophy-
laxis regimen for acute GvHD has not been well evaluated in
RIST, which is considered to require a sophisticated balance
between GvHD and a graft-versus-leukemia (GvL) effect.
To address these points, we conducted a prospective
randomized clinical trial to evaluate the safety and efficacy
of RIST with fludarabine and oral busulfan in patients aged
over 50 years and with appropriate GvHD prophylaxis. In
this report, the results of an interim analysis, including clini-
cal outcomes, complications, and chimerism kinetics, were
compared with those previously published in the literature.
Patients and Methods
Patient eligibility and accrual
Eligible patients ranged in age from 50 to 69 years (median 58.5,
range 51–68 years) and had a hematological malignancy, including
AML or acute lymphoblastic leukemia (ALL) in 1st or 2nd complete
remission (CR), CML in 1st or 2nd chronic phase (CP), and MDS. They
were required to have an HLA-identical related donor. The study protocol
was reviewed and approved by the institutional review boards of the partic-
ipating transplantation centers (Appendix). Eligible patients and their
donors gave written informed consent before enrollment. The enrollment
criteria included a performance status (PS) of the Eastern Cooperative
Oncology Group (ECOG) of less than two, a serum creatinine concentra-
tion of less than 2.0 mg/dl, a cardiac ejection fraction of more than 50%,
arterial oxygen saturation without supplemental oxygen of more than
93%, liver function tests less than fourfold the upper limit of normal, total
bilirubin less than 2.0 mg/dl, no active infection, and no previous allergy for
drugs used for conditioning or GvHD prophylaxis. Donors were required to
have a normal physical examination, and normal values in the serum
chemistry and blood counts, and negative results of serologic testing for
human immunodeficiency virus and hepatitis B. The patient and donor
characteristics are shown in Table I. Those with AML/ALL in 1st CR, CML
in 1st CP, or MDS in refractory anemia were defined as low risk, and the
others were defined as high risk. All 12 patients with MDS except one
(UPN 22) were transfusion dependent, and all those were grouped
according to the International Prognostic Scoring System (IPSS) into in-
termediate or high risk at the time of transplantation: Intermediate-1, n ¼
3; intermediate-2, n ¼ 6; high risk, n ¼ 3. By IPSS criteria, 3 patients had
good-risk, 3 had intermediate-risk, and 6 had poor-risk cytogenetics.
Donor selection and blood stem cell harvest
Related donors were selected based on compatibility of HLA-A, B
and DRB1 by intermediate- or high-resolution DNA typing. After G-CSF
treatment, apheresis procedures were performed daily until at least 2.0
 106 CD34+ cells per kilogram of the recipient’s body weight, up to
three times, and all of the collected cells were cryopreserved until stem
cell infusion.
TABLE I. Patient and Donor Characteristics
UPN Patient age/sex Donor age/sex Stage and diagnosis
IPSS/cytogenetic
risk in MDS patients CD34+ cells (106)
Blood type
patient/donor
1 60/M 46/F MDS (RA) Intermediate-2/Poor 03.92 A/A
2 61/M 54/F MDS (RAEB) Intermediate-2/Poor 05.84 O/O
3 67/M 60/F AML (M4) in 2CR 02.74 B/O
4 60/M 55/F AML (M2) in 2CR 04.58 B/B
5 63/M 60/M CML in 2CP 12.59 O/O
6 54/M 59/F MDS (RAEB) High/Intermediate 05.40 O/A
7 52/M 55/F AML (M2) in 1CR 06.77 A/A
8 61/M 54/M AML (M1) in 1CR 03.29 B/A
9 58/F 64/F CML in 1CP 02.90 A/AB
10 64/F 59/F ALL (L2) in 1CR 05.54 A/A
11 55/M 44/M AML (M1) in 1CR 03.13 A/A
12 55/F 51/F CML in 1CP 04.94 A/O
13 52/F 42/M AML (M4) in 1CR 03.59 A/A
14 59/M 64/M MDS (RAEB) Intermediate-2/intermediate 03.58 A/AB
15 59/M 56/M MDS (RA) Intermediate-1/Good 03.58 AB/A
16 53/F 55/F MDS (RA) Intermediate-2/Poor 02.20 O/O
17 55/F 68/M AML (M3) in 2CR 02.63 A/A
18 54/M 50/M MDS (RA) Intermediate-1/Poor 03.74 O/B
19 51/M 44/F AML (M1) in 1CR 04.86 AB/A
20 64/F 66/M CML in 2CP 03.59 O/A
21 68/F 64/M MDS (RAEB) Intermediate-1/Good 03.56 B/B
22 53/M 44/M MDS (RAEB) High/Intermediate 07.20 B/B
23 60/F 53/M AML (M2) in 1CR 02.83 A/B
24 59/M 62/M AML (M4) in 2CR 05.47 A/O
25 51/F 47/F MDS (RAEB) Intermediate-2/Poor 05.93 A/A
26 59/M 62/F MDS (RA) Intermediate-2/Poor 04.02 B/O
27 59/M 48/M AML (M2) in 2CR 04.94 B/A
28 56/M 62/F MDS (RAEB-t) High/Good 04.38 AB/A
29 53/F 62/F AML (M2) in 1CR 03.06 O/O
30 54/F 63/M AML (M2) in 1CR 06.47 A/O
M, male; F, female; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leu-
kemia; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CR,
complete remission; CP, chronic phase. All donors were HLA-matched siblings.
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Treatment schedule
The treatment schedule is shown in Fig. 1. The conditioning regimen
consisted of fludarabine (30 mg/m2/day) infused over 30 min once a
day on Days 8, 7, 6, 5, 4, and 3, and oral busulfan (4 mg/kg/day) on
Days 6 and 5. To prevent seizures, the patients received oral valproate
sodium, at a dose of 600 mg divided into 3 doses 2 days before busul-
fan administration, and this was continued until 24 hr after the last
dose of busulfan.
Patients were randomized to receive either cyclosporine (CyA) alone
or CyA plus short-term methotrexate (MTX) for GvHD prophylaxis.
Randomization was performed by stratifying according to disease
(AML, ALL, CML or MDS), transplant center, age (less than 60 years
or more than or equal to 60 years), and sex (male or female). All
patients received 3 mg/kg/day CyA by continuous iv infusion daily from
Day 1 to maintain a therapeutic trough level of 250–400 ng/ml, and
thereafter orally in an attempt to maintain a therapeutic trough level of
150–250 ng/ml. The patients who were assigned to CyA plus short-
term MTX received a dose of 10 mg/m2 iv MTX on Day +1, and 7 mg/
m2 on Days +3 and +6 after stem cell infusion. CyA was tapered start-
ing at Day 28 in the absence of acute GvHD and was discontinued by
Day 100 after transplantation. When a patient did not achieve complete
donor chimerism by Day 60, CyA was tapered rapidly and discontinued
within 2 weeks if clinically feasible, since anti-leukemic effect was pre-
sumed to occur after development of complete donor chimerism [14].
Cases of Grade II–IV acute GvHD were treated with 2 mg/kg/day of
methylprednisolone in addition to CyA.
Supportive care
The following infection prophylaxis was recommended: prophylactic
antibiotics (fluoroquinolones) were given during cytopenia, fluconazole
(200 mg/day) was given at the start of conditioning and continued until
the discontinuation of immunosuppressant, and oral acyclovir (1,000
mg/day) or iv acyclovir (750 mg/day) was given for prophylaxis of her-
pes simplex virus (HSV) and varicella zoster virus (VZV) from Day 7
to Day 35. Prophylaxis against Pneumocystis carinii was consisted of
trimethoprim-sulfamethoxazole after neutrophil engraftment (0.5 
109 L1) and was continued until the discontinuation of immunosup-
pressant. During the first 100 days after transplantation, cytomegalovi-
rus antigenemia assay with HRP-C7 or C10/C11 monoclonal antibody
was performed weekly after neutrophil engraftment until Day 100 after
transplantation. Pre-emptive therapy with ganciclovir was recom-
mended upon the detection of positive antigenemia and was continued
until it became negative. Patients were treated with G-CSF from Day
+6 to neutrophil engraftment.
Chimerism analysis
Hematopoietic chimerism was evaluated with regard to peripheral T
cell (CD3+) fraction by an analysis of DNA microsatellite polymor-
phisms by polymerase chain reaction (PCR) with D18S51, D20S471,
and D22S684 fluorescence-labeled primers, which identified differences
between patient and donor (on the basis of polymorphisms found in
pretransplant patient/donor samples) using an BECKMAN COULTER
CEQ8000 GENETIC ANALYSIS SYSTEM. T cell (CD3+) chimerism
studies post HSCT were performed on Days 30, 60, 90, 120, and there-
after every other month through 1 year.
Assessment of response
Day 0 was defined as the day of stem cell infusion day. The day of
neutrophil engraftment was defined as the first of two consecutive days
on which the patient’s absolute neutrophil count was above 0.5  109
L1. The day of platelet engraftment was defined as the first of seven
consecutive days on which the platelet count was above 20  109 L1
without platelet transfusion.
Regimen-related toxicity (RRT) was graded using the Seattle criteria
[18] on the day before the initiation of conditioning regimens and at
least 3 days a week until Day 20 after transplantation. All other
observed adverse events were graded according to the National Can-
cer Institute Common Toxicity Criteria version 2.0 (NCI-CTC ver. 2.0)
until Day 100 after transplantation. Infectious diseases were diagnosed
based on any positive blood culture or histologic evidence of tissue
invasion.
To evaluate the general condition of patients associated with the tox-
icity profile, PS, and dietary oral intake were also reported at least
three times a week during the initial hospitalization and once a week
afterwards up to Day 100 post-transplant.
The diagnosis and grading of acute and chronic GvHD was made
based on the date of onset (within or beyond 100 days) and clinical
findings in conjunction with biopsy of the skin and digestive tract using
the published criteria [19,20]. Patients who survived 100 days or longer
were evaluable for the assessment of chronic GvHD.
Pharmacokinetic studies of fludarabine
phosphate and busulfan
Blood sampling for pharmacokinetic studies was done on Day 5 to
investigate the effect of concomitant busulfan administration on the
pharmacokinetics of 2-fluoro-ara A (2F-ara-A), which is the major
metabolite of fludarabine phosphate. Blood samples for determining the
2F-ara-A plasma level were collected at 0, 0.5, 1, 2, 5, and 23.5 hr af-
ter the 4th infusion of fludarabine. We also obtained blood samples for
determining the busulfan plasma level at 0, 0.5, 1, 1.5, 2, 3, and 6 hr
after the sixth administration of busulfan (1 mg/kg/dose for 8 times).
Blood samples were taken in tubes containing heparin and erythro-9-
(2-hydroxy-3-nonyl)adenine. Plasma was obtained by centrifugation,
and then transported to the laboratory and were stored at 208C until
analysis. Plasma levels of 2F-ara-A and busulfan were determined
using high-performance liquid chromatography with fluorescence and
UV detection, respectively. The accuracy and precision of the assays
for 2F-ara-A and busulfan were confirmed by measuring QC samples
of both before this study. The maximum concentration of drug in
plasma after drug administration (Cmax, Cpeak) and the time to reach
Figure 1. Treatment schedule. CyA; cyclosporine, MTX; methotrexate. *1: When acute GvHD was not observed, CyA
was tapered by 10% a week starting at Day 28, and was eliminated by Day 100. When mixed chimerism was seen with-
out active acute GvHD over Day 60, CyA was tapered and discontinued within 2 weeks. Patients who did not convert to
complete chimerism after CyA withdrawal received donor lymphocyte infusion.
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the maximum concentration following drug administration (Tmax) were
observed. The area under the plasma concentration-versus-time curve
(AUC) for 2F-ara-A or busulfan was calculated by dividing the adminis-
tered dose by the final plasma clearance estimate, whereas the plasma
clearance was determined by modeling all plasma concentration versus
time data. Terminal half-lives (T1/2) were calculated from the primary
parameters.
Statistical analysis
The primary endpoint of this study was to determine the percentage
of patients who were alive at 100 days after transplantation with com-
plete donor chimerism (over 90%) achieved by Day 90. Secondary end-
points included the time to engraftment of neutrophils and platelets, the
incidence and severity of RRT, the incidence and severity of acute and
chronic GvHD, the anti-leukemia effect, DFS, and overall survival (OS).
A descriptive statistical analysis was performed to assess patient base-
line characteristics and disease. Time to engraftment, complete chimer-
ism, acute or chronic GvHD, OS, and DFS were calculated using the
Kaplan–Meier method. OS was defined as the time between stem cell
infusion to death from any cause. DFS was defined as the time
between stem cell infusion to relapse and death from any cause,
whichever occurred first. After 30 patients had been enrolled in the
study, a data and safety monitoring committee undertook an interim
analysis. This analysis, completed in October 2004, included data for
the primary endpoint, i.e. survival at Day 100 and chimerism status at
Day 90, and data on acute and chronic GvHD, survival, chimerism sta-
tus, and anti-tumor effect through Day 180. Neither of the predefined
criteria for stopping the study was met; however, a review of available
safety data including incidence and severity of RRT and Day 100 mor-
tality indicated that this conditioning regimen was adequately safe for
older patients. According to the recommendation of the committee, we
decided to continue the study and published an interim report when 30
patients were enrolled and evaluated without comparing the two differ-
ent GvHD prophylaxis procedures. This report includes data on these
30 patients with all available follow-up data through December 2005,
and does not include the results of a comparison of the two different
GvHD prophylaxis procedures.
Results
Engraftment and chimerism analysis
The results are summarized in Table II. One and four
patients were not evaluated for neutrophil and platelet
engraftment, respectively, because they did not show a na-
dir. The remaining patients achieved sustained engraftment
and none experienced graft failure. The median number of
days to achieve a neutrophil count  0.5  109 L1 was 13
(range, 10–25 days), and this was 18 (range, 11–24 days)
for a platelet count  20  109 L1 without transfusion.
Full-donor (over 90%) T-cell (CD3+) chimerism was
observed in 2 and 9 of the 30 patients on Day 30 and Day
60, respectively (median [range], Day 30:71 [40 to 90] %,
day 60:81 [41 to 90] %). Twenty-two patients achieved
full-donor chimerism, while the remaining eight patients had
mixed chimerism ranging from 78% to 88% on Day 90.
Among those with mixed chimerism on Day 90, five subse-
quently converted to full-donor chimerism without early CyA
withdrawal because of the severe acute GvHD (n ¼ 2:
UPN 1 and 15) and/or donor lymphocyte infusion (DLI) by
day 120 (n ¼ 4) or day 180 (n ¼ 1). One achieved full-do-
nor chimerism on Day 120 after DLI since the patient did
not respond to the discontinuation of immunosuppressive
drugs, and two had persistent mixed chimerism without
relapse through 180 days after transplantation (71% and
75% donor-type chimerism on Day 180). The diagnoses of
two patients with persistent mixed chimerism through Day
180 were CML and MDS, and they had not received pro-
ceeding cytotoxic chemotherapy; the patient with CML
(UPN 12) received immunomodulators, imatinib mesylate
and hydroxyurea, and the patient with MDS (UPN 21)
received low-dose cytarabine and aclarubicin in combina-
tion with granulocyte colony stimulating factor before RIST.
Regimen-related toxicities, complications,
and general condition
The frequencies of Grade I–IV organ toxicities within 20
days after transplantation are listed in Table III. Although
non-fatal toxicities including Grade I/II were seen in all 30
patients, all of the observed episodes were reversible and
in no case required suspension of fludarabine. Stomatitis
was the most frequently observed organ toxicity (57%, 17/
30), with 47% of them (8/17) had Grade II events. None of
the patients experienced veno-occlusive disease of the liver
(VOD). Twenty patients had at least one episode of infec-
tious complications within the first 100 days, with a total of
44 documented episodes (median, 2; range, 1–7 episodes)
within the first 100 days after transplantation. These
included proven bacterial infection (1 episode), suspected
bacterial infection (1), suspected fungal infection (2), cyto-
megalovirus antigenemia (6), HSV infection (1), suspected
viral infection (1), and uncertain causes (33). All infectious
complications were recovered with or without appropriate
antibiotic therapy.
The median PS for the first 28 days was 0 (range, 0–3).
The worst PS of 2 (n ¼ 5) or 3 (n ¼ 2) within the first 28
days was experienced temporarily due to infection (n ¼ 2),
Grade III GvHD (n ¼ 1), and nausea/vomiting (n ¼ 4).
Those (n ¼ 6) observed from Day 29 to Day 100 were all
caused by Grade II or III acute GvHD. A one-thirds reduc-
tion in dietary oral intake was temporarily seen in 20 and
11 patients within the first 28 days and from 29 days to 100
days post HSCT, respectively, which resulted from nausea/
vomiting (n ¼ 18) and treatment-related mucositis (n ¼ 2)
within Day 28, and Grade II–III acute GvHD (n¼ 9), prolonged
infection with Grade II acute GvHD (n¼ 1) and gastroesopha-
geal reflux disease (n¼ 1) between Day 29 and Day 100.
GvHD
Grade I–IV acute GvHD at 100 days was documented,
respectively, in 5 (17%), 15 (50%), 3 (10%), and 0 (0%)
patients. The median time to the occurrence of Grade II–IV
acute GvHD was 74 days (range, 18–100 days). All 30
patients survived beyond Day 100 and were evaluated for
chronic GvHD. Twenty-six of the 30 patients (87%) devel-
oped chronic GvHD (limited type in four cases and exten-
sive type in 22 cases) with the onset at a median of 123
days after transplantation (range, 116–217 days).
Disease response, survival, and cause of death
No patient died within the first 100 days, and the median
follow-up period was 555 days (149–1114 days) after trans-
plantation. Twenty-nine of the 30 patients achieved CR
within 100 days after transplantation, but two of them with
MDS, who had poor-risk cytogenetics and were classified
into intermediate-2, subsequently relapsed on Day 141
(UPN 26) and Day 156 (UPN 25). One was treated with
DLI (UPN 25) and showed a temporary response, but died
because of the disease progression on Day 401. The other
patient (UPN 26) did not respond to DLI and died of pro-
gressive disease on Day 412. One patient (UPN 22) with
MDS with high risk IPSS achieved full-donor chimerism on
Day 90, but could not achieve CR on Day 98 and died with
progressive disease on Day 306. This patient showed full-
donor chimerism through Day 180. Five other patients died
between 100 days and 1 year after transplantation (149,
151, 169, 187, and 354 days). In six patients who died
within the first year, two patients were over 60 years and
four patients were classified into high risk disease group.
Causes of death included progressive disease of MDS with
poor IPSS in 1, GvHD and/or its complications in 4, and re-
currence of interstitial pneumonia in 1. In four patients, who
died of GvHD and/or its complications, all had experienced
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gut GvHD, three of those developed extensive chronic
GvHD and all were treated with corticosteroid.
The Kaplan-Meier estimated probability of OS and DFS at
1 year was, respectively, 83% and 62% (Fig. 2). Both patients
age (55 years versus >55 years) and CD34+ cell dose (>5.0
 106 kg1 versus 5.0  106 kg1) were not associated with
better outcomes by a stratified analysis (data not shown).
Pharmacokinetic results for fludarabine and busulfan
2F-ara-A and busulfan PK parameters were calculated
from data obtained from blood samples from six consenting
patients (UPN 1, 3–7). After the start of the 4th infusion of
fludarabine phosphate (30 mg/m2/dose), the maximum
plasma level of 2F-ara-A was 3.12 ± 1.08 nmol/ml, with a
subsequent decline to T1/2 of 8.59 ± 1.57 h. The AUC (0–
24 hr) and CL were 17.7 ± 2.82 nmol hr/ml and 78.9 ±
13.1 ml/min/m2, respectively. After the 6th administration of
busulfan (1 mg/kg/dose for eight times), the maximum
plasma level of busulfan was 1.37 ± 0.34 nmol/ml, with a
subsequent decline to a T1/2 of 2.88 ± 0.65 hr. The AUC
(0–6 hr) and CL were 4.85 ± 1.07 nmol hr/ml and 3.60 ±
0.88 ml/min/m2, respectively. Since these parameters are
similar to those in a previous study with the repeated
administration of fludarabine phosphate alone at 15, 20,
and 25 mg/m2/dose (data not shown), combination with
busulfan seemed to have no effect on the pharmacokinetics
of 2F-ara-A. The steady-state plasma level of busulfan (808
± 178 ng/ml) was observed to remain within a therapeutic
level (600–900 ng/ml) in adults [21].
Discussion
In this prospective study, we showed that a combination
of fludarabine (180 mg/m2) and oral busulfan (8 mg/kg), de-
spite the omission of antithymocyte globulin from the origi-
nal regimen by Slavin et al. [6], can be successfully used to
help prepare patients older than 50 years with hematologi-
cal malignancies for HSCT from an HLA-matched related
donor: All patients achieved sustained engraftment without
graft failure, only an insignificant occurrence of RRT and
treatment-related complications were seen, and PS and
dietary intake were well maintained, which agrees with pub-
lished observational studies on RIST with fludarabine and
busulfan [16,22,23].
The rapid induction of complete donor-type chimerism
was considered as an essential part of the RIST procedure.
Although all of our patients rapidly developed conventional
neutrophil and platelet engraftment, two of the 30 patients
without preceding cytotoxic chemotherapy remained in
mixed T-cell chimerism during the first 6 months after trans-
plantation. A more rapid induction of T-cell chimerism has
been observed in other studies of RIST in patients who had
been previously treated with chemotherapy for diseases
other than CML or MDS [24]. Although a close association
between the occurrence of acute GvHD and the induction
of higher levels of donor T-cell chimerism has been
reported [14], in our experience over 50% of patients did
not achieve complete chimerism at the onset of acute
GvHD, demonstrating that mixed chimerism status did not
provide absolute protection from GvHD, which is in agree-
ment with data published by Baron et al. [15]. We speculate
that differences in the conditioning regimen and GvHD pro-
phylaxis may result in different observations.
While our less intensive regimen was associated with
less toxicity, this strategy will only work if modifications to
the conditioning regimen intensity that allow early clinical
benefits do not also lead to reduced induction of GvL effect
or other complications that increase relapse rate or result
in worse survival in later time period [25]. A recent obser-
vational study from European Group of Blood and Marrow
Transplantation Registry compared treatment-related mor-
tality (TRM) and other outcomes between 315 RIST recipi-
ents and 407 CIST recipients, who were over 50 years and
transplanted from a HLA matched sibling donor [26], and
suggested that lower TRM but higher relapse rate were
seen in RIST recipients. Given the fact that all three
patients, who relapsed within 6 months after transplanta-
tion, were MDS with poor prognostic factors, the incidence
of relapse in our study seems to be no higher than that in
published data for CIST [27–30]. Taussig et al. evaluated
the feasibility and safety of the fludarabine based RIST regi-
men in 16 patients with standard risk diseases [31]. In this
study, TRM rate within 100 days was 0%, however, OS and
DFS at 1 year read from Fig. 2 were 69% and 56%,
respectively, where most of the patients included in this
study had early stage diseases and over 30% of patients
were aged less than 50 years. Despite the older patient
population, our data showing no treatment-related mortality
(TRM) within the first 100 days after transplantation and
OS and DFS at 1 year of 83% and 62%, respectively, was
encouraging.
In a previous report, we suggested that the development
of GvHD is not essential for the control of low-risk myeloid
malignancies, and that GvHD and infection, rather than
relapse, are more important problems to be addressed in
these patients [25]. Although our data showed favorable
outcomes, six patients with four low risk disease and three
patients aged less than 55 years died of GvHD or its com-
plication within the first year should be interpreted with
care. The incidence of Grade II–IV acute GvHD in this
TABLE III. Regimen-Related Toxicities Within 20 Days After HSCT
According to the Seattle Criteria in 30 Patients
Toxicity
Grade
1 2 3 4
Heart 1 0 0 0
Bladder 0 1 0 0
Kidney 5 1 0 0
Lung 2 0 0 0
Liver 8 0 0 0
CNS 1 0 0 0
Stomatitis 9 8 0 0
GI toxicity 4 1 0 0
HSCT, hematopoietic stem cell transplantation; CNS, central nervous
system; GI, gastro-intestinal. Figure 2. Kaplan–Meier product estimates of overall sur-
vival and disease-free survival.
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study was somewhat higher than that in published literature
and our own observational data with elder patients and
high risk diseases [25]. However, Grade III–IV acute GvHD
was infrequent and none died from acute GvHD. The inci-
dence of chronic GvHD was higher than that in our previ-
ous experience (56%) [32] or in other reports [31,33] even
after considering inevitable differences in the ethnicity,
GvHD prophylaxis and matching practice of HLA, or dis-
ease risk. G-CSF mobilized peripheral blood stem cells
may have been associated with an increased incidence of
GvHD, particularly in its chronic form [34,35]. Conditioning
regimen excluded antithymocyte globulin was also a possi-
ble explanation of this finding [23]. Most importantly,
patients undergoing RIST are usually older than those
undergoing CIST, which leads to a higher risk for GvHD
[36,37]. Early CyA withdrawal regulation to get speedy
achievement of complete donor chimerism after RIST in
our protocol might have influenced the increased incidence
of Grade II–IV acute GvHD, which might have affected the
rate of chronic GvHD [33,35,38,39]. Although severe GvHD
will be unavoidable for some patients including MDS with
poor prognostic factors [40,41], the balance between GvHD
and GvL is a significant concern in RIST and we should
seriously evaluate the type and tapering speed of immuno-
suppressive agents after RIST. Current findings suggested
GvHD control might be improved simply by extending the
duration of CyA administration. Additionally, we noticed that
the clinical features of GvHD are different in RIST than in
CIST, i.e. a syndrome compatible with acute GvHD occurs
well after Day 100. Hence, the current grading system for
GvHD, which was developed on the basis of experience in
ablative settings, may not be an optimal tool for assessing
GvHD after RIST. We observed a late onset of acute GvHD
and an early onset of chronic GvHD, and therefore believe
that a significant number of late-onset acute GvHD may
have been judged as chronic GvHD in this study simply
because the onset of GvHD was over 100 days after trans-
plantation. Our results support the current proposition by
Mielcarek and Storb concerning the abandonment of the
traditional Day 100 cutoff for separating acute from chronic
GvHD [35].
In this prospective study, we confirmed the short-term
safety and efficacy of our RIST procedure for hematological
malignancies in the elderly. Long-term follow-up of patients
to evaluate disease control and the consequence of therapy
is mandatory, and the development of optimal GvHD pro-
phylaxis, with the use of novel assessment criteria, will be
of primary importance for the wider application of the RIST
procedure. RIST may also be beneficial in young patients,
since organ damage, including infertility, might be milder
and less frequent in RIST than in CIST, which should be
confirmed by further prospective clinical trials. Although the
number of patients studied was limited, the analysis of flu-
darabine pharmacokinetics has for the first time provided
reliable information on the interaction of key drugs, and we
found no evidence to suggest that synergic or specific tox-
icities were associated with increased exposure to the con-
comitant use of busulfan, or vice versa. This information
should be useful in future studies in which different drugs
are combined with fludarabine.
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